| Detailed information |
|---|
| CancerLivER ID | 2585 |
| Biomarker | RPNI, ZNF161, EIF4G1, FNBP3, CCT6A, PPIB, IMPA2, GORASP2, KIAA0669, ATP2A2, PA200, ZNF91, GOLGA4, KIAA0494, SIAH1, UBQLN2, ADNP, TPD52L2, FDPS, DICER1 |
| Biomarker Name/Symbol (given in Publication) | Ribophorin I or RPNI, Zinc finger protein 161 or ZNF161, Eukaryotic protein synthesis initiation factor 4 gamma or EIF4G1, Formin binding protein 3 or FNBP3, Chaperonin containing TCP1 subunit 6A (zeta 1) or CCT6A, Alanyl-tRNA synthetase or AARS, Peptidylprolyl isomerase B or PPIB, Inositol(myo)1(or 4)-monophosphatase 2 or IMPA2, Splicing factor proline/glutamine rich or SFPQ, Ataxin 2 related protein or A2LP, Golgi reassembly stacking protein 2 55 kDa or GORASP2, KIAA0669 gene product or KIAA0669, ATPase Ca++ transporting cardiac muscle slow twitch 2 or ATP2A2, Proteasome activator 200 kDa or PA200, Actin beta or ACTB, Zinc finger protein 91 or ZNF91, Golgi autoantigen golgin subfamily a 4 or GOLGA4, KIAA0494 gene product or KIAA0494, Seven in absentia homolog 1 (Drosophila) or SIAH1, Sp3 transcription factor or SP3, Ubiquilin 2 or UBQLN2, Activity-dependent neuroprotector or ADNP, Tumor protein D52-like 2 or TPD52L2, Farnesyl diphosphate synthase or FDPS, Dicer1 Dcr1 homolog (Drosophila) or DICER1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in G2 than G1 (with fisher ratio more than 1.7) |
| Level of significance | P < 0.005 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | pathogenesis of HCV-related HCC and not HBV-associated HCC |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |